Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India

Netravathi, M; Bollampalli, Hari Krishna; Bhat, Maya; Ganaraja, Valakunja Harikrishna; Prasad, Shweta; Mahadevan, Anita; Kamble, Nitish; Nalini, Atchayaram; Yadav, Ravi; Pal, Pramod Kumar; Satishchandra, P

doi:10.1016/j.msard.2019.01.032

Cited by 19 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As with previous studies the most frequent form of relapse in NMOSD was a lesion of the spinal cord and the frequency observed in the present study (48%) falls in the middle of previous observations (36-63%) (11)(12)(13)(14)(15). The frequencies of other relapse types were similar to these prior studies.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation

et al. 2020

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

“…As with previous studies relapses with encephalitic or other cerebral features were uncommon in NMOSD. Area postrema lesions as an initial presenting feature was seen in (9%) which was similar to prior studies (15). We found that area postrema relapses were more common at first presentation than with subsequent relapses.…”

Section: Discussionsupporting

confidence: 90%

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation

et al. 2020

View full text Add to dashboard Cite

“…Then, it is reasonable to think that other factors may be associated with a better outcome following TPE, and it may be useful to consider these when making treatment decisions or considering expectations. In NMOSD, these factors include anti-AQP4 seronegativity (patients who are seronegative for anti-AQP4 but seropositive for anti-myelin oligodendrocyte glycoprotein generally present better outcomes) [ 12 ] and combination treatments with immunosuppressants [ 34 ]. In GBS, additional factors include the number of exchanges on the basis of the severity of disease [ 35 ] and the patient's age [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease

Nieto-Aristizábal

Vivas

Ruiz-Montaño

et al. 2020

Autoimmune Diseases

View full text Add to dashboard Cite

Introduction. Therapeutic plasma exchange (TPE) is commonly used as treatment of certain autoimmune neurological diseases (ANDs), and its main objective is the removal of pathogenic autoantibodies. Our aim was to describe the clinical profile and the experience with the usage of TPE in patients with ANDs at our institution. Methods. This is an observational retrospective study, including medical records of patients with diagnosis of ANDs who received TPE, between 2011 and 2018. Characteristics of TPE, such as number of cycles, type of replacement solution, and adverse effects, were evaluated. The modified Rankin Scale (mRS) was applied to measure the clinical response after the therapy. Results. 187 patients were included with the following diagnoses: myasthenia gravis (MG), n = 70 (37%); Guillain–Barré syndrome (GBS), n = 53 (28.3%), neuromyelitis optica spectrum disorders (NMOSD), n = 35 (18.7%); chronic inflammatory demyelinating polyneuropathy (CIDP), n = 23 (12.2%); and autoimmune encephalitis (AE), n = 6 (3.2%). The most used types of replacement solution were albumin (n = 131, 70%) and succinylated gelatin (n = 45, 24%). All patients received a median of five cycles (IQR 5-5). Hypotension and hydroelectrolytic disorders were the main complications. After TPE, 99 patients (52.9%) showed improvement in the mRS scores and a statistical significance (p<0.05) was seen between the admission score and after TPE for every diagnosis except for CIDP. Conclusion. TPE has an adequate safety profile, and improvement in functionality in treated patients reflects its effectiveness.

show abstract

“…After excluding reviews and case reports, 13 articles that described clinical, demographic features, investigations including testing for AQP4-IgG and MOG-IgG were included. [39][40][41][42][43][44][45][46][47][48][49][50][51] These are listed chronologically in Table 2.…”

Section: Demographic and Clinical Features Of Nmosd In Indiamentioning

confidence: 99%

“…With the recent availability of commercial diagnostic kits (Euroimmun, Germany) for detection of AQP4-IgG & MOG-IgG, several papers have been published with definitive diagnosis of seropositive NMOSD from different parts of India. These included studies which described clinical features of AQP4-IgG-positive 39,40,45,46 and MOG-IgG-positive patients, 43,44,49,51 studies highlighting seroprevalence among patients with atypical demyelinating disorders 42 and comparative studies of demyelinating disorders from different regions of India. 48,50 Pediatric demyelinating disorders have been described from hospital settings.…”

Section: Demographic and Clinical Features Of Nmosd In Indiamentioning

confidence: 99%

Epidemiology and clinical features of demyelinating disorders in India

Pandit

Mustafa

2021

Neurology & Clinical Neurosc

View full text Add to dashboard Cite

In tropical countries like India, noncommunicable diseases have traditionally received less priority over infectious diseases. In recent times, however, demyelinating disorders of the central nervous system have become recognized as an important group of noncommunicable neurological disorders in India. It is possible that increasing awareness among doctors on one hand and availability of magnetic resonance imaging facilities (MRI) in teaching and private hospitals in the metropolitan cities of India on the other have contributed to early diagnosis and treatment.The study of demyelinating disorders of the nervous system in India has been limited by many factors. Kurtzke's 1 epidemiological studies pointed to India as having a low prevalence for multiple sclerosis (MS). Neuromyelitis optica (NMO) was considered a variant of MS. In the pre-MRI era, diagnosis of MS centered around clinical

show abstract

Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India

Cited by 19 publications

References 25 publications

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation

Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation

Therapeutic Plasma Exchange as a Treatment for Autoimmune Neurological Disease

Epidemiology and clinical features of demyelinating disorders in India

Contact Info

Product

Resources

About